shr-1918
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 2022 (NCT05432544)
Timeline
Indications
Mechanism of action
- Angiopoietin-related protein 3INHIBITOR
ANGPTL3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07308392 | Phase 2 | Dec 31, 2025 | Jiangsu ShengDiYa Medicine Co., Ltd. |
| NCT07230730 | Phase 3 | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07133815 | Phase 2 | Aug 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06723652 | Phase 3 | Dec 31, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06471218 | Phase 2 | Jun 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06109831 | Phase 2 | Nov 30, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06009393 | Phase 2 | Sep 24, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05432544 | Phase 1 | Jul 1, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 7 | 7 | 3 | 2022 |
| Jiangsu ShengDiYa Medicine Co., Ltd. | Government | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1